OBJECTIVE: To evaluate the role of postchemotherapy adjunctive surgery in patients with liver metastases from germ cell cancer (GCT). PATIENTS AND METHODS: Forty-three male patients with nonseminoma were treated in different multicenter treatment protocols between 1990 and 1999, and they underwent hepatic surgery. The results of postchemotherapy surgical resection, histologic findings found during postchemotherapy surgery, and prognostic factors for survival were assessed. RESULTS: Thirty-five of 43 patients (81%) were initially diagnosed with liver metastases and advanced GCT, and 8 patients (19%) presented with metachronous liver metastases after a median interval of 16 months (range, 6-103 months). Twelve patients (28%) had isolated liver metastases after completion of chemotherapy, while 31 patients (72%) had additional residual extrahepatic tumor masses. Liver surgery included tumor excision or segmentectomy in 32 patients (74%) and hepatectomy (right/left) or resection of multiple segments in 11 patients (26%). Histologic analysis of postchemotherapy resected residua yielded necrosis in 67%, teratoma in 12%, and viable cancer in 21%. Additional resections at other sites have been performed in 31 patients revealing necrosis in 61% (n = 19), teratoma in 29% (n = 9), and vital carcinoma in 10% (n = 3). In 39% of patients, histologic findings differed among liver and other resection sites. Refractoriness to chemotherapy was associated with a shorter survival after surgery, and a trend was seen in patients with elevation of AFP. CONCLUSION: The high rate of viable cancer and teratoma found in liver specimens, differing histologic results at residual tumor locations, and the high survival rate achieved support a multidisciplinary approach including resection of liver masses since no accurate selection of patients can narrow the use of surgery.
OBJECTIVE: To evaluate the role of postchemotherapy adjunctive surgery in patients with liver metastases from germ cell cancer (GCT). PATIENTS AND METHODS: Forty-three male patients with nonseminoma were treated in different multicenter treatment protocols between 1990 and 1999, and they underwent hepatic surgery. The results of postchemotherapy surgical resection, histologic findings found during postchemotherapy surgery, and prognostic factors for survival were assessed. RESULTS: Thirty-five of 43 patients (81%) were initially diagnosed with liver metastases and advanced GCT, and 8 patients (19%) presented with metachronous liver metastases after a median interval of 16 months (range, 6-103 months). Twelve patients (28%) had isolated liver metastases after completion of chemotherapy, while 31 patients (72%) had additional residual extrahepatic tumor masses. Liver surgery included tumor excision or segmentectomy in 32 patients (74%) and hepatectomy (right/left) or resection of multiple segments in 11 patients (26%). Histologic analysis of postchemotherapy resected residua yielded necrosis in 67%, teratoma in 12%, and viable cancer in 21%. Additional resections at other sites have been performed in 31 patients revealing necrosis in 61% (n = 19), teratoma in 29% (n = 9), and vital carcinoma in 10% (n = 3). In 39% of patients, histologic findings differed among liver and other resection sites. Refractoriness to chemotherapy was associated with a shorter survival after surgery, and a trend was seen in patients with elevation of AFP. CONCLUSION: The high rate of viable cancer and teratoma found in liver specimens, differing histologic results at residual tumor locations, and the high survival rate achieved support a multidisciplinary approach including resection of liver masses since no accurate selection of patients can narrow the use of surgery.
Authors: J T Hartmann; C R Nichols; J-P Droz; A Horwich; A Gerl; S D Fossa; J Beyer; J Pont; L Kanz; L Einhorn; C Bokemeyer Journal: Ann Oncol Date: 2002-07 Impact factor: 32.976
Authors: H J Schmoll; R Souchon; S Krege; P Albers; J Beyer; C Kollmannsberger; S D Fossa; N E Skakkebaek; R de Wit; K Fizazi; J P Droz; G Pizzocaro; G Daugaard; P H M de Mulder; A Horwich; T Oliver; R Huddart; G Rosti; L Paz Ares; O Pont; J T Hartmann; N Aass; F Algaba; M Bamberg; I Bodrogi; C Bokemeyer; J Classen; S Clemm; S Culine; M de Wit; H G Derigs; K P Dieckmann; M Flasshove; X Garcia del Muro; A Gerl; J R Germa-Lluch; M Hartmann; A Heidenreich; W Hoeltl; J Joffe; W Jones; G Kaiser; O Klepp; S Kliesch; L Kisbenedek; K U Koehrmann; M Kuczyk; M P Laguna; O Leiva; V Loy; M D Mason; G M Mead; R P Mueller; N Nicolai; G O N Oosterhof; T Pottek; O Rick; H Schmidberger; F Sedlmayer; W Siegert; U Studer; S Tjulandin; H von der Maase; P Walz; S Weinknecht; L Weissbach; E Winter; C Wittekind Journal: Ann Oncol Date: 2004-09 Impact factor: 32.976
Authors: H-J Schmoll; C Kollmannsberger; B Metzner; J T Hartmann; N Schleucher; P Schöffski; J Schleicher; O Rick; J Beyer; D Hossfeld; L Kanz; W E Berdel; R Andreesen; C Bokemeyer Journal: J Clin Oncol Date: 2003-10-20 Impact factor: 44.544
Authors: Jan Oldenburg; G Cecilie Alfsen; Hans H Lien; Nina Aass; Håkon Waehre; Sophie D Fossa Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 44.544
Authors: Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann Journal: Drugs Date: 2006 Impact factor: 9.546